30
Participants
Start Date
February 10, 2025
Primary Completion Date
May 31, 2027
Study Completion Date
December 31, 2027
MDMA
Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
Cognitive Processing Therapy
Participants will receive 8-15 (average of 12) sessions of Cognitive Processing Therapy
MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)
Participants assigned to MDMA-aCPT will undergo a therapeutic approach administered by trained therapists. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. MDMA can elicit feelings of empathy, love, and deep appreciation, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present. A combined treatment of MDMA and therapy may be especially useful for treating PTSD because MDMA can attenuate the fear response of a perceived threat to one's emotional integrity and decrease defensiveness without blocking access to memories or preventing a deep and genuine experience of emotion.
RECRUITING
VA Palo Alto Health Care System / Stanford University, Palo Alto
Stanford University
OTHER
VA Palo Alto Health Care System
FED
Steven & Alexandra Cohen Foundation
OTHER
Patricia Suppes
OTHER